

Product Datasheet

BRM/BRG1 ATP Inhibitor-1

Catalog No. **BP-02223** · CAS **2270879-17-7** · Form **free base** · Physical state **other** · Color **White to off-white** · Version **1.0** · Revision **2026-09-02**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target SWI/SNF Complex	Research area Cancer
----------------------------------	--------------------------------

Molecular formula **C₁₁H₉F₃N₄O₂S**

Molecular weight **318.2750**

STRUCTURE



DESCRIPTION

BRM/BRG1 ATP Inhibitor-1 is an allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC₅₀s are below 0.005 μM.

BIOLOGICAL ACTIVITY

In Vitro

BRM/BRG1 ATP Inhibitor-1 (compound 14) (0-10 μM, 5 days) can inhibit the proliferation of cancer cells.

BRM/BRG1 ATP Inhibitor-1 inhibits KRT80 gene expression in H1299 cells with the AAC₅₀ (absolute AC₅₀) value of 0.01 μM and in RERF-LC-AI cells with an AAC₅₀ value of 0.01 μM.

In Vivo

BRM/BRG1 ATP Inhibitor-1 (compound 14) (oral administration, 7.5 or 20 mg/kg, everyday, 3 weeks) can inhibit tumor growth and inhibit KRT80 expression in a dose-dependent manner.

SOLUBILITY

Soluble in DMSO

In vitro DMSO : 200 mg/mL

REFERENCES

[1]. Papillon JPN, et al. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers. J Med Chem. 2018 Nov 21;61(22):10155-10172

Lot CoA and SDS are separate documents.